FLEURY S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.9 BRL | -6.73% |
|
-6.08% | -22.95% |
| Mar. 08 | Transcript : Fleury S.A., Q4 2023 Earnings Call, Mar 08, 2024 | |
| Mar. 07 | Fleury S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2024 * | 7.8B 1.49B | Sales 2025 * | 8.37B 1.6B | Capitalization | 7.57B 1.44B |
|---|---|---|---|---|---|
| Net income 2024 * | 616M 117M | Net income 2025 * | 790M 151M | EV / Sales 2024 * | 1.41 x |
| Net Debt 2024 * | 3.44B 656M | Net Debt 2025 * | 3.07B 585M | EV / Sales 2025 * | 1.27 x |
| P/E ratio 2024 * |
12.7
x | P/E ratio 2025 * |
9.73
x | Employees | 27,300 |
| Yield 2024 * |
2.46% | Yield 2025 * |
5.6% | Free-Float | 43.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fleury S.A.
More press releases
| 1 day | -6.86% | ||
| 1 week | -5.58% | ||
| Current month | -7.47% | ||
| 1 month | -7.03% | ||
| 3 months | -17.63% | ||
| 6 months | -9.87% | ||
| Current year | -23.06% |
1 week
13.81
14.82
1 month
13.8115.37
Current year
13.8118.08
1 year
13.1918.96
3 years
12.8926.55
5 years
12.8932.47
10 years
6.1032.47
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 00-12-31 | |
| Director of Finance/CFO | 63 | 21-07-22 | |
| Chief Tech/Sci/R&D Officer | 48 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | - | |
| Director/Board Member | 78 | 13-04-08 | |
João Teixeira
BRD | Director/Board Member | 57 | 21-04-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.43% | 2 M€ | -14.14% | ||
| 0.24% | 15 M€ | -4.90% | ||
| 0.02% | 4 M€ | -4.41% | - | |
| 0.01% | 117 M€ | -1.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 13.9 | -6.73% | 7 622 100 |
| 24-04-17 | 13.88 | -1.14% | 3,837,600 |
| 24-04-16 | 14.04 | -1.96% | 4,805,700 |
| 24-04-15 | 14.32 | -2.72% | 4,511,000 |
| 24-04-12 | 14.72 | -0.54% | 2,497,300 |
Delayed Quote Sao Paulo, April 17, 2024 at 04:07 pm EDT
More quotes
Fleury S.A. specializes in clinical diagnosis, treatment and analysis services.
At the end of 2018, the group operated a network of 187 patient care centers and 23 hospital centers under Fleury, Weinmann, Clínica Felipe Mattoso, a +, Labs a + and Diagnoson a + brands.
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
13.88
BRL
Average target price
19.8
BRL
Spread / Average Target
+42.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.06% | 1.45B | |
| -19.00% | 8.01B | |
| +37.47% | 3.52B | |
| -26.35% | 2.98B | |
| -7.18% | 2.48B | |
| -10.74% | 2.31B | |
| -15.45% | 1.75B | |
| -38.05% | 1.27B | |
| -9.20% | 1.08B | |
| +4.07% | 1.07B |
- Stock Market
- Equities
- FLRY3 Stock
